Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Prospective, Multicenter, Randomized, Double Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients With Diabetic Macular Edema

NCT04857996 is registered in ClinicalTrials.gov with Unity Biotechnology, Inc. as lead sponsor.

NCT NCT04857996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04857996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Prospective, Multicenter, Randomized, Double Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients With Diabetic Macular Edema
Lead sponsor
Unity Biotechnology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 25, 2021
Completion date
April 6, 2023
Enrollment
65 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema (dme)